EUCTR2009-017859-98-NL进行中（未招募）不适用
A Randomized, Double-Masked, Placebo-Controlled Study of PRM-151 in the Prevention of PostoperativeScarring in Glaucoma Patients Following Primary Trabeculectomy - PRM-151 Trabeculectomy Scarring Prevention v.1
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men or women of nonchildbearing potential (WONCBP) aged 18 years and older at screening. WONCBP may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for =1 year (with follicle stimulating hormone [FSH] =38 mIU/mL) and must have a negative pregnancy test result at screening. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound. Sexually active men must agree to use a medically acceptable form of contraception during the study.
- •2. Diagnosis of chronic angle-closure glaucoma or open-angle glaucoma, phakic or pseudophakic, with visual field or optic disc changes characteristic of glaucoma. For pseudophakic glaucoma patients, the cataract surgery performed was with phacoemulsification and through a corneal incision.
- •3. Suitable candidate for trabeculectomy in the study eye which the physician deems as medically necessary.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Diagnosis of glaucoma other than chronic angle-closure glaucoma or open-angle glaucoma (ie., uveitic, traumatic or neovascular glaucoma).
- •2. Any previous ocular surgeries in the study eye involving the upper conjunctiva and sclera.
- •3. History of laser surgeries in the study eye within 90 days before day 1.
- •4. Presence or history of any disease that could affect wound healing.
- •5. Any asymmetric abnormality of the anterior segment which requires additional intervention (surgery or medication).
- •6. Any abnormality other than glaucoma in the study eye that could affect tonometry.
- •7. Presence or history of uveitis within 10 years or any other ocular infection or inflammation within 14 days before day 1.
- •8. Presence or history of any abnormality or disorder that could interfere with the study procedure or prevent the successful completion of the study.
- •9. Clear corneal phacoemulsification performed within 90 days before day 1.
- •10. Any significant unstable cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
- •11. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article or the assessment of the effect of the test article.
- •12. History of drug abuse or alcohol abuse within 1 year before screening that may interfere with the subject’s ability to comply with the protocol requirements.
- •13. Conjunctival scarring precluding a trabeculectomy.
- •14. Vitreous in the anterior chamber.
- •15. Proliferative retinopathy.
- •16. Abnormality preventing reliable applanation tonometry in each eye.
- •17. History of drug anaphylaxis to any of the test articles used in this study.
- •18. Hemodialysis.
- •19. Use of any anti-scarring ophthalmologic agents within 90 days before day 1.
- •20. Use of antimetabolites or systemic steroids within 90 days before day 1.
- •21. Treatment with cancer chemotherapy within 30 days before day 1.
- •22. Use of any investigational drug within 30 days before day 1.
研究者
相似试验
进行中（未招募）
1 期
Glaucoma Surgery Scarring Prevention StudyPRM-151, a novel agent, is being developed for potential therapeutic uses to prevent, treat and reduce fibrosis. This study will investigate the ability of PRM-151 to prevent scarring post glaucoma filtration surgery (trabeculectomy).MedDRA version: 14.1 Level: PT Classification code 10018304 Term: Glaucoma System Organ Class: 10015919 - Eye disordersEUCTR2009-017859-98-GBPromedior Inc120
进行中（未招募）
1 期
Glaucoma Surgery Scarring Prevention StudyPRM-151, a novel agent, is being developed for potential therapeutic uses to prevent, treat and reduce fibrosis. This study will investigate the safety and tolerability as well as the influence of PRM-151 on scarring and wound healing after glaucoma filtration surgery (trabeculectomy).MedDRA version: 14.1Level: PTClassification code 10018304Term: GlaucomaSystem Organ Class: 10015919 - Eye disordersEUCTR2009-017859-98-BEPromedior Inc120
进行中（未招募）
不适用
Glaucoma Surgery Scarring Prevention StudyPRM-151, a novel agent, is being developed for potential therapeutic uses to prevent, treat and reduce fibrosis. This study will investigate the ability of PRM-151 to prevent scarring post glaucoma filtration surgery (trabeculectomy).MedDRA version: 15.0Level: PTClassification code 10018304Term: GlaucomaSystem Organ Class: 10015919 - Eye disordersEUCTR2009-017859-98-CZPromedior Inc120
进行中（未招募）
不适用
Efficacy and safety of gevokizumab in the treatment of patients with active non-infectious uveitison-infectious Intermediate, Posterior, or Pan- UveitisMedDRA version: 14.1Level: PTClassification code 10022557Term: Intermediate uveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10069034Term: Tubulointerstitial nephritis and uveitis syndromeSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10033687Term: PanuveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10036370Term: Posterior uveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10071139Term: Behcet's uveitisSystem Organ Class: 100000004870MedDRA version: 14.1Level: LLTClassification code 10066681Term: Acute uveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10042745Term: Sympathetic uveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10012692Term: Diabetic uveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2012-001610-42-ESXOMA (US) LLC300
进行中（未招募）
不适用
Efficacy and safety of gevokizumab in the treatment of patients with active non-infectious uveitison-infectious Intermediate, Posterior, or Pan- UveitisMedDRA version: 17.0Level: PTClassification code 10022557Term: Intermediate uveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 17.0Level: PTClassification code 10069034Term: Tubulointerstitial nephritis and uveitis syndromeSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 17.0Level: LLTClassification code 10033687Term: PanuveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 17.0Level: LLTClassification code 10036370Term: Posterior uveitisSystem Organ Class: 100000004862MedDRA version: 17.0Level: LLTClassification code 10066681Term: Acute uveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 17.0Level: LLTClassification code 10071139Term: Behcet's uveitisSystem Organ Class: 100000004866MedDRA version: 17.0Level: LLTClassification code 10042745Term: Sympathetic uveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 17.0Level: PTClassification code 10012692Term: Diabetic uveitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 17.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2012-001610-42-DEXOMA (US) LLC300